# Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais

> **NCT01666262** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mahidol University** · enrollment: 363 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Vaccine A/17/CA/2009/38 (H1N1)
- **OTHER:** Placebo:Stabilizer

## Key facts

- **NCT ID:** NCT01666262
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** —
- **Final completion:** 2012-01
- **Target enrollment:** 363 (ACTUAL)
- **Last updated:** 2012-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01666262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01666262, "Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01666262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*